A relativity concept in mesenchymal stromal cell manufacturing by Martin, Ivan et al.
A relativity concept in mesenchymal stromal cell manufacturing
IVAN MARTIN1, JAN DE BOER2 & LUC SENSEBE3 ON BEHALF OF THE MSC
COMMITTEE OF THE INTERNATIONAL SOCIETY FOR CELLULAR THERAPY
1Department of Biomedicine, University Hospital Basel, Basel, Switzerland, 2Merln Institute for Technology-inspired
Regenerative Medicine,Maastricht University,Maastricht,The Netherlands, and 3UMR5273 STROMALab Centre
National de la Recherche Scientifique (CNRS)/Établissement Français du Sang (EFS)/Universite Paul Sabatier
(UPS), Institut National de la Sante et de la Recherche Médicale (INSERM),U1031,Toulouse, France
Abstract
Mesenchymal stromal cells (MSCs) are being experimentally tested in several biological systems and clinical settings with
the aim of verifying possible therapeutic effects for a variety of indications. MSCs are also known to be heterogeneous popu-
lations, with phenotypic and functional features that depend heavily on the individual donor, the harvest site, and the culture
conditions. In the context of this multidimensional complexity, a recurrent question is whether it is feasible to produce MSC
batches as “standard” therapeutics, possibly within scalable manufacturing systems. Here, we provide a short overview of
the literature on different culture methods for MSCs, including those employing innovative technologies, and of some typ-
ically assessed functional features (e.g., growth, senescence, genomic stability, clonogenicity, etc.).We then offer our perspective
of a roadmap on how to identify and refine manufacturing systems for MSCs intended for specific clinical indications. We
submit that the vision of producing MSCs according to a unique standard, although commercially attractive, cannot yet be
scientifically substantiated. Instead, efforts should be concentrated on standardizing methods for characterization of MSCs
generated by different groups, possibly covering a vast gamut of functionalities. Such assessments, combined with hypoth-
eses on the therapeutic mode of action and associated clinical data, should ultimately allow definition of in-process controls
and measurable release criteria for MSC manufacturing. These will have to be validated as predictive of potency in suit-
able pre-clinical models and of therapeutic efficacy in patients.
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Introduction
The clinical use of mesenchymal stromal cells (MSCs)
for tissue regeneration, immune modulation or graft
enhancement has reached dimensions deserving serious
consideration and critical discussion by the scientific
and clinical communities [1]. Indeed, even high-
profile journals have provided the forum for
controversial debates, either challenging the sound-
ness of putative therapeutic modes by MSCs or
advocating their legitimate clinical experimentation
despite the absence of demonstrated biological mecha-
nisms [2]. Beyond the extreme positions taken by
opposite fringes, it is becoming apparent that the field
requires well-designed randomized, prospective, con-
trolled trials that deliver quantitative outcome measures,
on the basis of which it will be possible to verify or
reject specific hypotheses.
To enable such trials, manufacture of MSC batches
becomes of primary importance. It is necessary at this
stage to make a distinction between those trials in
which a “small-scale” production of MSCs is suffi-
cient, for example, in an autologous use setting, from
those which require the manufacture of 10 000 or more
doses, typically for allogeneic transplants, in which
large-scale production models are likely key to eco-
nomic sustainability. Obviously, the latter can only be
based on extensive expansion of MSCs, which in turn
opens several questions about preservation of func-
tion and onset of senescence.
MSC preparations are considered advanced therapy
medicinal products by European regulation (Euro-
pean Commission [EC] 1394/2007). In the United
States, they are considered a more-than-minimal-
manipulated cellular and gene therapy product
regulated under section 351 of the Public Health
Service Act (42 U.S.C. 262). In Europe, MSCs as ad-
vanced therapy medicinal products require an
authorization of national regulatory authorities from
the countries involved in a clinical trial. In the United
States, for conducting clinical trials using MSCs, it
is mandatory to have an approved Investigational New
Drug Application from the Food & Drug Adminis-
tration. Although some differences exist between
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Europe and the United States, in both cases, MSCs
should be produced according to Good Manufactur-
ing Practice (GMP) rules, associated with the
requirement to define suitable release criteria and/or
potency assays.
In this context, the purpose of the present article
is to offer a concise perspective on the parameters to
be considered in the production of large MSC batches
and how these can be modulated by specific culture
systems and operating conditions. A strategy is then
proposed to define manufacturing processes integrat-
ing scientific developments and clinical perspectives
with prospected industrial exploitation, in compli-
ance with regulatory pathways.
Onset of senescence during MSC expansion
When MSCs are transferred from their native niche
to a polystyrene culture dish, they change from small,
mostly quiescent cells, to spindle-shaped, actively pro-
liferating cells (Figure 1). At early passages, the cells
divide about once a day, which contributes to their
popularity for therapeutic purposes. It should be re-
alized, however, that expansion comes at a price. As
their time in culture progresses, their proliferation rate
declines, and depending on the donor and culture con-
ditions, MSCs enter a state of replicative senescence
after 20–30 cell divisions [3–5]. During this process,
MSC morphology changes from relatively small
spindle-shaped cells to larger and flattened cells, with
typically more pronounced actin cytoskeleton fibers.
Concomitant with the process of senescence, MSCs
tend to progressively lose their multi-potency. Espe-
cially well-documented effects are the loss of in vitro
differentiation into the osteogenic, chondrogenic and
adipogenic lineages after culture expansion, which
occurs at an earlier population doubling than senes-
cence itself, and does not occur at the same time for
all lineages [6,7].
Loss of multi-potency and onset of senescence in-
dicate that MSC properties change during culture
expansion. Surprisingly, the conventional panel of
cluster of differentiation (CD) markers used to char-
acterize MSCs is only marginally affected. Thus,
although the typical CD “signature” can be used to
confirm the mesenchymal stromal nature of MSCs (i.e.,
positivity for CD73, CD90 and CD105) [8], surface
markers correlating to MSC function and multi-
potency are largely lacking [9].The expression of several
factors such as alkaline phosphatase and STRO-1 does
decline after culture expansion, but is not reliably
predictive of differentiation capacity or other
immunomodulatory properties [10].
MSCs are telomerase-negative cells and culture ex-
pansion is associated with a decrease in telomere length,
which begins at the start of culture [11]. A number
of immortalized MSC lines have been reported
[12–15], exhibiting maintained multi-potency and thus
suggesting a causal relationship between the two.
Culture expansion has also been implicated in issues
related to genomic stability. MSCs accumulate DNA
damage during expansion, and an increase in DNA
adducts such as 8-oxo guanine have been reported
[6,16]. Moreover, after about 15 population doublings,
Figure 1. Changes in MSC morphology. Scanning electron microscopic image of a human bone marrow biopsy, 24 h after seeding onto
tissue culture polystyrene. The image depicts the different shapes of cells, from small and rounded representing the native shape in the
bone marrow, to cells that recently attached to the surface and large flat cells, which have spread and will start proliferating. Some non-
adherent, round cells are likely of hematopoietic origin, including red blood cells displaying a concave morphology.
614 I. Martin et al.
MSCs activate a DNA damage response, which occurs
at around the same time as loss of multi-potency and
before cells enter quiescence. It is well known that
DNA damage can be mutagenic, and telomere loss
is associated with genomic instability. This raises the
concern that MSC expansion is associated with an in-
crease in genomic mutations, which may lead to
tumorigenesis upon implantation. However, sponta-
neous immortalization is almost never seen in human
cells, in contrast to mouse cells, and the authors of
this article have never observed spontaneous immor-
talization of MSCs or tumorigenicity upon implantation
in vivo.This is supported by extensive cytogenetic anal-
ysis of human MSCs during culture expansion, which
revealed their large genomic stability [17–19]. Indeed,
when spontaneous immortalization of MSCs was re-
ported, it was later attributed to the contamination of
the culture with tumor cell lines [20]. However, other
reports do describe genomic instability [3] corre-
lated to oxidative damage.
Although senescence seems inevitable during ex-
tensive expansion, the biological properties of MSCs
can be strongly influenced by the composition of the
culture medium [21,22]. One important source of
chemical heterogeneity is fetal bovine serum (FBS),
which is still used for most MSC expansion proto-
cols. MSCs grown in different serum batches display
large differences in proliferation rate and differenti-
ation, such that many labs devote considerable time
to testing different batches of serum. FBS is no longer
considered as an option for clinical applications, where
autologous serum is preferred [23], with the associ-
ated disadvantages of donor variability and limited
standardization [24].Alternatively, platelet lysate may
be used as substitute for serum [25]. Although donor
specific differences in platelet lysate activity on bone
marrow derived MSCs were also reported [26], plate-
let lysate has the advantage of containing non-
xenogeneic products and to be a potent source of growth
factors that is safe, reliable, practical and affordable,
at least for small-scale academic production runs. Many
xenogeneic serum-free and chemically defined medium
formulations have also been reported in the litera-
ture.These media, although highly promising, are not
yet homogeneous in formulation and contain diverse
sets of factors, therefore leading to controversial results
and additional variability/complexity in the field of MSC
culture expansion [27,28]. Moving forward with chem-
ically defined medium to standardize culture conditions
requires groups to state the formulation used, despite
issues with intellectual property.This would also have
the advantage of de-risking medium supply during clin-
ical development by not having to rely on a single
supplier.
One of the most potent enhancers of MSC growth
that is typically used in serum-free medium formu-
lations and also as an additional supplement to reduce
batch-to-batch serum variability is FGF2 [29]. The
example of FGF2 is paradigmatic for the potential ben-
efits and risks of expanding MSCs in the presence of
growth factors. In fact, FGF2 stimulates MSC pro-
liferation and maintains a less differentiated phenotype
as well as a superior clonogenicity and multilineage
differentiation capacity, possibly by selecting earlier pro-
genitor populations with longer telomeres [29].
However, FGF2-expanded MSCs have a reduced ca-
pacity to support hematopoiesis and consistently
express HLA-DR, with yet unpredictable conse-
quences in the immunomodulatory and immuno-
privileged properties [30].
The level of oxygen at which MSCs are expanded
is known to influence their properties. In general, cell
culture under normoxia poses high oxidative stress on
the cells, and senescence is delayed under low oxygen
levels. Expansion under hypoxia may positively affect
multi-potency [31,32] but may also skew the differ-
entiation capacity of MSCs [33]. In this regard, it is
important to remark that culture conditions typical-
ly report the levels of oxygen in the air as v/v% and
in many cases using only the ill-defined terms
“hypoxia” or “normoxia.” Instead, the relevant culture
variable is the percentage of dissolved oxygen in the
culture medium, which can greatly vary in culture
dishes despite the nominal level being settled in the
incubator air. Standardization of the parameter is
crucial and can be best achieved when cell culture is
performed in monitored/controlled bioreactor systems,
as discussed in the next section.
Alternative MSC culture systems
Studies on different cellular systems have recognized
that maintenance of “early progenitor” properties may
be favored by the establishment of a tissue-specific mi-
croenvironment or niche. This principle has fostered
the search for culture conditions that are possibly more
“physiological” for MSCs than a traditional petri dish
made of a rigid polystyrene material. Considering that
the extracellular matrix (ECM) comprises impor-
tant components of the niche, different groups have
tested the possibility to grow MSCs on petri dishes
coated with ECM molecules. In particular, it was dem-
onstrated that denatured collagen coating improves the
osteogenic and adipogenic differentiation capacity of
human bone marrow–derived MSCs [34]. To mimic
the stromal environment where MSCs are found in
vivo, the use of devitalized ECM laid down by MSCs
as substrate for their growth was also investigated.
Results convincingly indicated a more efficient pres-
ervation of SSEA-4+, clonogenic MSCs, which retained
their ability to form bone tissue in vivo after exten-
sive passaging [35].
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Chemical [36], stiffness [37] and geometric [38]
modifications to materials have been implicated in the
lineage specification and differentiation of MSCs. Re-
cently, it was shown that defined nano-topographical
patterns embossed in culture substrates can be used
to maintain undifferentiated MSCs, possibly by regu-
lating intracellular tension [39].These studies highlight
the complexity of interactions among several sub-
strate parameters and call for the development of high-
throughput technologies to identify improved material
surfaces [40].
Various attempts have been reported to expand
MSCs in three-dimensional (3D) environments, for
example, with suspension culture in the presence of
dynamic flow [41] or using microcarrier beads [42].
On the basis of the analogy with other industries, these
systems would have a large potential to drive down
production costs, at the same time allowing for moni-
toring and control of relevant parameters, which are
important during process standardization. Despite the
promising results obtained, however, these studies
achieved a rather limited number of cell doublings
during the 3D culture. Moreover, the approaches
require an initial phase of MSC growth on plastic,
which is intrinsically associated with selection of the
adherent cellular fractions and the loss of most he-
matopoietic lineage cells. Indeed, non-mesenchymal
or non-adherent bone marrow cells were proposed to
be involved in regulating MSC function and have been
demonstrated to enhance growth of MSCs with
clonogenic properties [43,44].
An alternative strategy for MSC expansion relies
on directly loading and culturing freshly harvested bone
marrow cells into the pores of 3D scaffolds, thereby
entirely bypassing the initial phase of selection on Petri
dishes [45,46].The system, which requires the use of
a perfusion-based bioreactor system to improve the
efficiency of MSC seeding and nutrition, supported
the scalable expansion of clonogenic MSCs, with a
transcriptomic profile closer to stem cell signatures
[47]. Although no formal proof has been provided, the
effect could be mediated by the generation of an ex
vivo “stromal niche” [48], leading to the preserva-
tion in the culture system of subpopulations of earlier
MSC progenitors less efficiently adhering [44] and/
or of hematopoietic cells. The same paradigm was
successfully validated for the growth of adipose tissue–
derived MSCs, in which a population of functional
endothelial lineage cells, otherwise lost in serial pas-
saging, was preserved [49] and was instrumental in
achieving accelerated engraftment of the correspond-
ing engineered tissues [50]. It should, however, be
pointed out that strategies based on MSC co-culture
with supporting populations, although promising in
their capacity to reproduce their native environ-
ment, require a downstream sorting system to eliminate
the non-mesenchymal accessory cells and may intro-
duce the challenge to harvest cells from the porous
scaffolds without detriment to the functionality of the
final product.
A roadmap toward suitable MSC
manufacturing protocols
This short overview highlights the broad spectrum of
MSC phenotypes and functions that can be reached
by different culture protocols, obviously challenging
the possibility to define a “standard” for MSCs or for
a MSC manufacturing system. Recognizing that the
conceptual framework around the use of MSCs is
strictly dependent on the intended therapeutic appli-
cation, we propose here a possible roadmap toward
the identification of matching MSC culture condi-
tions (Figure 2). In our view, the starting point of the
process is the definition of a precise clinical indica-
tion, according to which a specific hypothesis on the
mechanism of action of the delivered cells will have
to be formulated. Such postulated therapeutic mode
should in turn guide the definition of possible release
criteria for the batches of MSCs to be grafted. For
example, an expected direct contribution of MSCs to
tissue regeneration may imply the need to maintain
a differentiation capacity toward a certain lineage or
possibly even multi-potency. Instead, the putative “hit-
and-run” effect potentiating the repair mechanisms of
endogenous cells may require assessing the secretion
of molecules (e.g., interleukin-4, interleukin-1RA, pros-
taglandin 2) capable of establishing a “regenerative
niche” (e.g., by inducing monocyte polarization toward
M2) [25]. In this same perspective, recent papers have
outlined a gamut of possible assays to quantitatively
capture the immune modulatory properties of MSCs,
toward the establishment of release criteria for the treat-
ment of specific autoimmune or inflammatory diseases
[51–53]. For example, functionality tests for MSCs
to be used in clinical indications targeting immune
disorders have been proposed to include changes
in response to interferon-γ licensing, based on
cytofluorimetric, mRNA gene expression and
proteomic levels [54].The same approach should be
initiated for MSCs used in other clinical fields. Despite
the ongoing controversies and challenges, it is be-
coming increasingly clear that currently used surface
markers are not likely to capture specific MSC
functionalities and that “defining robust and predic-
tive markers and assays of potency remains the Gordian
knot in the field” [53].The complexity may be further
increased by the fact that the criteria of “purity” typical
for drugs and single cell populations need to be ex-
tended to multipotent cellular products such as MSCs,
where interaction of diverse cell subpopulations may
drive their effectiveness.
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With all the arbitrary assumptions that are nec-
essary at early stages in development of new strategies,
it is, in the authors’ view, imperative that a set of tar-
geted properties and their respective release criteria
be defined for each intended clinical indication and
that these drive the definition of culture conditions
allowing maximizing the maintenance/acquisition of
such properties. It is unlikely that the same batch of
MSCs, even if well standardized and quality con-
trolled, will be effective for the diversity of clinical
indications that are currently being targeted using MSC
preparations. Moreover, to be able to retrospectively
revise the definition of the MSC features most di-
rectly predictive of clinical outcome, alternative
parameters should be measured beyond those re-
quired for the initially selected release criteria. In a
different area of cellular therapy, namely limbal stem
cells for corneal regeneration, this strategy based on
post hoc analyses has led to the identification of p63
expression as a parameter quantitatively associated with
successful transplantation [55]. An additional element
of complexity is related to the characterization of the
cells before or after banking, because freshly thawed
MSCs (i.e., in the typical state at the time of deliv-
ery) may display distinct biological properties from
those typically examined in pre-clinical studies (i.e.,
in the log phase of growth) [56].
At this stage, MSC culture that is in compliance
with GMP would be ready for clinical testing. As pre-
viously mentioned, the trial should follow design criteria
that allow, as much as possible, to test a specific hy-
pothesis that could inform on the proposed mechanism
of action or possibly lead to the formulation of a dif-
ferent one. Results will ultimately determine whether
Definition of specific 
clinical indication
Hypothesis on MSC 
mode of action
Development of culture 
conditions and associated In-
Process-Controls to achieve 
the defined release criteria
Definition of batch size 
and manufacturing 
system
Clinical trial: 
Phase I (safety) 
Phase II (efficacy/dose 
testing)
Assessment of clinical efficacy
Specification of targeted 
properties and of #cells/dose 
according to potency assays,
and definition of release 
criteria 
Evaluation of  
bioreactor-based 
technologies 
Figure 2. Proposed roadmap for MSC manufacturing. The definition of a specific clinical indication targeted by the delivery of MSCs
should be based on a mode of action, postulated even arbitrarily on the basis of pre-clinical models. This should lead to the definition of
targeted properties for MSCs, including the development of release criteria for vitality, identity, purity and potency, hypothesized to be
predictive for the clinical outcome, and in turn guiding the selection of culture parameters monitored and controlled by in-process con-
trols (IPC). At this stage, culture conditions should be identified that satisfy the selected IPC and lead to a product meeting the specific
release criteria (RC). The parallel assessment of novel bioreactor-based technologies supporting scalable, standardized and possibly auto-
mated processes should lead to the definition of a manufacturing system to be used for cell production for a clinical trial. The clinical
efficacy observed in such a trial should then be assessed in view of a possible correlation with the selected IPC and/or RC and the defined
number of cells per dose. This could lead to a validation/refinement of the targeted properties and/or RC, or to the need to correct the
intended clinical indications and/or underlying hypothesis in an iterative process (dashed lines). This roadmap could obviously be consid-
ered for manufacturing other cell types in cellular therapy.
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the target indication, along with the specific inclusion/
exclusion criteria, need to be refined or more drastically
considered inappropriate. Importantly, in the context
of manufacturing, analysis of the number of cells pre-
scribed for a graft dose will have to be combined with
the extent of expansion allowing the defined release
criteria to be maintained.Together, these data will offer
an indication on the number of possible doses per
MSC batch and therefore on the scalability of the
process.
To industrialize manufacturing, a scaled-up or -out
process, respectively, for allogeneic or autologous prepa-
rations should consider implementation in bioreactor
systems, within a controlled physicochemical culture
environment (e.g., in terms of dissolved oxygen or pH).
Indeed, the introduction of monitoring features should
simplify traceability and regulatory as well as safety
compliance. Process automation within closed systems
(e.g., for automated medium exchange during culture
or streamlined storage operation) is expected to lead
to minimized operator handling, improved reproduc-
ibility, possibility of predominant operation is GMP
environments of Class C (as opposed to the more costly
ones in Class A) and, as a consequence of all this, to
superior cost-effectiveness. The introduction of
bioreactor systems as early as possible in the phase
of process definition, although requiring large upfront
investments, has been critical for industrial exploita-
tion in other biotech sectors (e.g., production of drugs,
antibodies or vaccines). In the specific context of MSC
expansion, bioreactor systems could go beyond rep-
licating with robotic systems the sometimes-ineffective
manual protocols and instead lead to streamlined, more
effective manufacturing processes addressing the most
critical scientific, regulatory and commercial chal-
lenges [57].
Conclusions
The extent of MSC expansion and the specific culture
conditions critically regulate the phenotype, func-
tion and onset of senescence of MSCs.To date, in the
absence of clinical data supporting the correlation of
specific MSC properties with unambiguous positive
outcome, no MSC preparation can be considered
“standard” even if deriving from certified manufac-
turers. Although targeting standardized MSC
preparations is likely to restrict scientific inquiry and
innovation, standardization of protocols and of func-
tional measurements is pivotal to bring continuity of
data interpretation to the field [58].To assess manu-
facturing comparability during process scale-up or
between manufacturing sites, it was proposed that an
MSC reference or calibration standard be estab-
lished [59].This proposition would not be conceptually
sound if it was intended to generate a cell gold standard
(i.e., MSCs representing a reference “optimal” bio-
logic activity) because a scientific basis for that is not
yet available [60]. Instead, the purpose of the cell ruler
would be to “serve as a common calibration tool and
provide a central data point, against which variation
in any dimension could be reported” [61]. Even within
this conceptual framework, however, several opera-
tional challenges related to sources, protocols, costs
and distribution for a cell ruler remain. In a simpli-
fied framework, what then needs to be introduced are
standard methods and guidelines to extensively char-
acterize MSCs in parallel with their in vivo
implantation.
We thus submit that following the proposed logic
will maximize the chances of developing safe and ef-
fective uses for MSCs that are compliant with the
sometimes-discrepant regulatory rules among differ-
ent countries, as part of advanced toolkits for routine
clinical practice. The process will also be relevant,
thanks to the investigations on the underlying modes
of action, to potentiate the biological functionality of
MSC products and/or specialized delivery systems (e.g.,
by manufacturing MSCs genetically modified to
express/overexpress trophic factors) [62].This might
ultimately lessen the large doses that are currently nec-
essary, thereby reducing the burden on GMP.
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